RATIONALE: The 2007 American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) recommend that patients with pulmonary nontuberculous mycobacterial (PNTM) disease caused by Mycobacterium avium complex (MAC) or M. abscessus be treated with a macrolide-based multidrug antibiotic regimen until sputum culture negative for 1 year. After 6 years, the degree of adherence to recommended guidelines among physicians remains unknown. OBJECTIVE: To describe antibiotic treatment practices among physicians treating patients with PNTM in the United States. METHODS: A nationally representative sample of 1,286 U.S. physicians was contacted in December 2011 through January 2012; 582 of the responding physicians were treating patients with PNTM and were eligible to participate. Physicians were asked to extract medical record data on the last four patients they treated in the past year with PNTM disease from either MAC or M. abscessus. Treatment patterns were assessed for all patients by NTM species and physician specialty, and compared with the 2007 recommended ATS/IDSA guidelines. MAIN RESULTS: Questionnaires were completed by 349 physicians on 915 patients with PNTM, including 744 (81%) with MAC and 174 (19%) with M. abscessus; 3 patients were positive for both. Physicians treated 76 (44%) patients with M. abscessus and 411 (55%) patients with MAC. Only 13% of antibiotic regimens prescribed to patients with MAC met ATS/IDSA guidelines, 56% did not include a macrolide, and 16% were for macrolide monotherapy. Among patients with M. abscessus, 64% of regimens prescribed did not include a macrolide. CONCLUSIONS: Adherence to the 2007 ATS/IDSA guidelines for treating PNTM disease is poor. Across all physician specialties evaluated, suboptimal or potentially harmful antibiotic regimens were commonly prescribed.
RATIONALE: The 2007 American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) recommend that patients with pulmonary nontuberculous mycobacterial (PNTM) disease caused by Mycobacterium avium complex (MAC) or M. abscessus be treated with a macrolide-based multidrug antibiotic regimen until sputum culture negative for 1 year. After 6 years, the degree of adherence to recommended guidelines among physicians remains unknown. OBJECTIVE: To describe antibiotic treatment practices among physicians treating patients with PNTM in the United States. METHODS: A nationally representative sample of 1,286 U.S. physicians was contacted in December 2011 through January 2012; 582 of the responding physicians were treating patients with PNTM and were eligible to participate. Physicians were asked to extract medical record data on the last four patients they treated in the past year with PNTM disease from either MAC or M. abscessus. Treatment patterns were assessed for all patients by NTM species and physician specialty, and compared with the 2007 recommended ATS/IDSA guidelines. MAIN RESULTS: Questionnaires were completed by 349 physicians on 915 patients with PNTM, including 744 (81%) with MAC and 174 (19%) with M. abscessus; 3 patients were positive for both. Physicians treated 76 (44%) patients with M. abscessus and 411 (55%) patients with MAC. Only 13% of antibiotic regimens prescribed to patients with MAC met ATS/IDSA guidelines, 56% did not include a macrolide, and 16% were for macrolide monotherapy. Among patients with M. abscessus, 64% of regimens prescribed did not include a macrolide. CONCLUSIONS: Adherence to the 2007 ATS/IDSA guidelines for treating PNTM disease is poor. Across all physician specialties evaluated, suboptimal or potentially harmful antibiotic regimens were commonly prescribed.
Authors: David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop Journal: Am J Respir Crit Care Med Date: 2007-02-15 Impact factor: 21.405
Authors: David E Griffith; Barbara A Brown-Elliott; Brett Langsjoen; Yansheng Zhang; Xi Pan; William Girard; Kenwyn Nelson; James Caccitolo; Julio Alvarez; Sara Shepherd; Rebecca Wilson; Edward A Graviss; Richard J Wallace Journal: Am J Respir Crit Care Med Date: 2006-07-20 Impact factor: 21.405
Authors: E Tanaka; T Kimoto; K Tsuyuguchi; I Watanabe; H Matsumoto; A Niimi; K Suzuki; T Murayama; R Amitani; F Kuze Journal: Am J Respir Crit Care Med Date: 1999-09 Impact factor: 21.405
Authors: Megan E Billinger; Kenneth N Olivier; Cecile Viboud; Ruben Montes de Oca; Claudia Steiner; Steven M Holland; D Rebecca Prevots Journal: Emerg Infect Dis Date: 2009-10 Impact factor: 6.883
Authors: Alicen B Spaulding; Yi Ling Lai; Adrian M Zelazny; Kenneth N Olivier; Sameer S Kadri; D Rebecca Prevots; Jennifer Adjemian Journal: Ann Am Thorac Soc Date: 2017-11
Authors: Julie V Philley; Mary Ann DeGroote; Jennifer R Honda; Michael M Chan; Shannon Kasperbauer; Nicholas D Walter; Edward D Chan Journal: Curr Treat Options Infect Dis Date: 2016-10-11
Authors: N El-Zeenni; S Chanoine; C Recule; J-P Stahl; M Maurin; B Camara Journal: Eur J Clin Microbiol Infect Dis Date: 2017-10-24 Impact factor: 3.267
Authors: Betty A Forbes; Geraldine S Hall; Melissa B Miller; Susan M Novak; Marie-Claire Rowlinson; Max Salfinger; Akos Somoskövi; David M Warshauer; Michael L Wilson Journal: Clin Microbiol Rev Date: 2018-01-31 Impact factor: 26.132
Authors: Patrick A Flume; David E Griffith; James D Chalmers; Charles L Daley; Kenneth Olivier; Anne O'Donnell; Timothy Aksamit; Shannon Kasperbauer; Amy Leitman; Kevin L Winthrop Journal: Chest Date: 2020-08-24 Impact factor: 9.410